Clinical trial NCT02673593: Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects
Official title: A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS102 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Safety
Pharmacokinetics
Food Effect
Lead sponsor: DS Biopharma
Sponsor class: INDUSTRY
First posted: 2016-02-04
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of the study is to investigate the safety, pharmacokinetics and food effect of DS102 (up to 2000mg single and multiple daily doses) and placebo in healthy participants.

DS102 capsules will be orally administered for up to 4 weeks, and will be compared against placebo.

The study will enrol approximately 56 adult subjects.

Detailed description: There will be 7 cohorts enrolled, each consisting of 8 subjects.

Cohorts 1 - 4 will be orally administered up to 2000mg single doses of DS102 on Day 1.

Cohorts 5 - 7 will be orally administered up to 2000mg multiple daily doses of DS102 for 28 days.

The primary objective is to assess the safety and plasma pharmacokinetics of single and multiple daily oral doses of DS102.

Eligibility criteria: Inclusion Criteria:

* Subject is male or female and is aged between 18 and 45 years inclusive.
* Subject's body mass index (BMI) is between 18.0 and 30.0 kg/m2 inclusive.
* Subject is a non-smoker, has been a non-smoker for 3 months prior to screening and has a negative urine cotinine test at screening.

Exclusion Criteria:

* Subject has had a clinically significant illness in the 4 weeks before screening.
* Use of prescribed medication in the 2 weeks before dosing or over-the-counter preparations (including vitamins and supplements) for 1 week before dosing
* Subject has a significant history of drug/solvent abuse, or a positive drugs of abuse (DOA) test at screening or Day -1.
* Subject with a history of alcohol abuse in the opinion of the Investigator, or who currently drinks in excess of 28 units per week (males) or 21 units per week (females), whereby a unit consists of 10ml or 8mg of pure alcohol, or who have a positive alcohol urine test at screening or Day -1.
* Subject has participated in any other clinical study with an investigational drug/device within 3 months before the first day of administration of study treatment.
* Subject has a positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen or Hepatitis C antibodies at screening.
* Subject has had a serious adverse reaction or significant hypersensitivity to any drug.
* Subject has donated blood or blood products within 3 months before screening.
* Subject has known hypersensitivity to any ingredients of the study treatment.

Primary outcomes:
measure: Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by Vz/F ) of DS102 administered as a single dose
timeFrame: 14 days
measure: Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a single dose
timeFrame: 14 days
measure: Safety (adverse events, laboratory tests, vital signs, ECGs) of DS102 administered as a multiple dose for 28 days
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by Cmax) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by tmax) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by AUC0-inf) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by AUClast) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by CL/F) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by Vz/F) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by AUC 0-24) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by Css) of DS102 administered as a multiple dose
timeFrame: 42 days
measure: Pharmacokinetics (Plasma concentrations assessed by t½) of DS102 administered as a multiple dose
timeFrame: 42 days
Secondary outcomes:
Other outcomes:
Locations:
city: Belfast
country: Ireland
facility: DS Biopharma Investigational Site
Study officials:
References: